



## 12<sup>th</sup> SEACFMD Laboratory Network Meeting

4-5 November 2019

Pakchong, Thailand



# Report of Proficiency Testing for FMD Laboratories in SEA including plans for 2019-2021 national and SEA

**Kingkarn Boonsuya Seeyo**

**REGIONAL REFERENCE LABORATORY FOR FMD IN SOUTH EAST ASIA (RRLSEA)  
PAKCHONG, NAKHONRATCHASIMA, THAILAND**

- **Objectives**

- To evaluate the performance of individual operators or laboratory staff.
- To evaluate the laboratory capability to conduct specific diagnostic test.
- Requirement of the **ISO/IEC 17025:2005 that have been ISO/IEC 17025:2017** standard for laboratory testing to apply for accreditation or upgrade approved tests.

Type of Program	YEAR	Round	Scope	Participants	Status
<b>Inter – Laboratory Comparison Testing</b>	2017	5 <sup>th</sup>	<ul style="list-style-type: none"> <li>✓ Antigen detection with ELISA typing test</li> <li>✓ FMD serology by liquid phase blocking ELISA (LP ELISA) and NSPs test</li> </ul>	<ul style="list-style-type: none"> <li>-Nation Lab</li> <li>-SEACFMD Lab</li> </ul>	Finished
<b>PROFICIENCY TESTING SCHEME</b>	2018	6 <sup>th</sup>	<ul style="list-style-type: none"> <li>✓ Antigen detection with ELISA typing test and <b>PCR</b></li> <li>✓ FMD serology by liquid phase blocking ELISA (LP ELISA) and NSPs test</li> </ul>	<ul style="list-style-type: none"> <li>-Nation Lab</li> <li>-<b>Animal quarantine service center</b></li> <li>-SEACFMD Lab</li> <li>(Did not delivery)</li> </ul>	Finished
<b>PROFICIENCY TESTING SCHEME</b>	2019	7 <sup>th</sup>	<ul style="list-style-type: none"> <li>✓ Antigen Detection of Foot and Mouth Disease (FMD) Diagnosis with ELISA Typing Test and <b>PCR</b></li> <li>✓ FMD serology by liquid phase blocking ELISA (LP ELISA) and NSPs test</li> </ul>	<ul style="list-style-type: none"> <li>-Nation Lab</li> <li>-<b>Animal quarantine service center</b></li> <li>-SEACFMD Lab</li> <li>- AFRICA Lab</li> </ul>	On going

# PROFICIENCY TESTING SCHEME (Round 6<sup>th</sup> / 2018)

## Foot and Mouth Disease (FMD) Diagnosis

### ❖ Antibody detection

#### □ PT serum sample

No.	Name/Details
1	Cattle serum Post Challenge O189 14 day
2	Cattle serum safety test Bivalent O189, Asakol 14 day
3	Newborn Calf serum Lot no:CP14-1 191 Exp.:05/2019
4	Cattle serum safety test Trivalent O189, Asakol, Asia1 28 days (Booster 14 days)
5	Cattle serum safety test Mono type A118/87

#### □ Interpretation of LP (Internal Control)





1. OD value of Antigen Control as 0.9-1.5
2. Percent Inhibition (%PI) of strong positive control serum  $\geq 90$
3. Percent Inhibition (%PI) of weak positive control serum (C+)  $\geq 50$
4. Percent Inhibition (%PI) of negative control serum (C-)  $< 50$

#### □ Interpretation of NSP (Internal Control)

1. OD value of Max  $\geq 1.00$
2. Percent Inhibition (%PI) of strong positive control  $\geq 70$
3. Percent Inhibition (%PI) of weak positive control (C+)  $\geq 50$


❖ **Antibody titer of PT sample** should not be less than  $\pm 2$  Two-fold dilution of **Reference titer\***

# Internal Quality Control of LP ELISA Testing




# Internal Quality Control of 3ABC NSPs Testing

▪ OD value (Max.)  
as Company  
standard





▪ Weak positive  
control and  
Positive control  
as Company  
standard





# Results of LP-ELISA



## Type O



## Type A




## Type Asia1



# Results of 3ABC NSPs Test


## %Percent Inhibition (PI) of 3ABC NSPs Test






# Z-Score

**Between  
Laboratory**



**Systematic  
Error**

**Within  
Laboratory**



# PROFICIENCY TESTING SCHEME (Round 6<sup>th</sup> / 2018)

## Foot and Mouth Disease (FMD) Diagnosis

### ❖ Antigen detection

PT sample	Sample 1	Sample 2	Sample 3	Sample 4	Sample 5	Sample 6
<b>Detail</b>	PBS	Inactivated FMDV serotype A (High OD)	Inactivated FMDV serotype A (Low OD)	Inactivated FMDV serotype O	Inactivated FMDV serotype Asia1 (High OD)	Inactivated FMDV serotype Asia1 (Low OD)
<b>PT result</b>	NVD	A (Strong)	A (Weak)	O	Asia1 (Strong)	Asia1 (Weak)

**Remark:** All of sample had checked inactivation by Virus Isolation before distribution.

List	Lower control limit (LCL)	Upper control limit (UCL)
<b>OD of Control Antigen (Antigen Detection)</b>	1.3	1.8




Figure 1. Overview of antigen typing result from each laboratory, Cut off OD  $\geq 0.20$  defined as positive






Figure 2 Overview IQC data of OD antigen control type 0, A and Asia1 at dilution 1:1 by ELISA Typing per laboratory, an acceptance OD control should be in range 1.3-1.8.

## Results ELISA Typing test



Sample 2 and 3



Sample 5 and 6

# Plan for PT 2019

Meeting and plan



Preparation and send invitation letter



Participation reply



Coordination and send PT samples




Testing

Send results

Analysis

Report

# Plan to consideration in 2019



❖ **Round 7<sup>th</sup> / 2019**  
**(On going invitation and distribution to participants)**

# Acknowledgment



## Working Group

Working group in PT program are listed as follows;

- Dr. Romphruke Udon
- Dr. Kingkarn Boonsuya Seeyo
- Dr. Karnrawee Suanpat
- Miss Janya Samanit
- Miss Piyaporn Chareonpol
- Dr. Sahawatchara Ungvanijban
- Dr. Amonrat Choonnassard
- Miss Sopha Singlebut
- Mr. Alongkon Puntumart



**Thank you for your participation**



12th SEACFMD Laboratory Network  
Meeting, 4-5 November 2019, Pakchong,  
THAILAND